Condition (MeSH)
Neoplasms, Unknown Primary
ClinicalTrials.gov lists 100 trials for Neoplasms, Unknown Primary or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
100 of the 100 trials are tagged with Neoplasms, Unknown Primary itself; the rest are tagged with a narrower condition beneath it.
When did Neoplasms, Unknown Primary trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 8 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 4 |
| 2016 | 5 |
Showing 10 of 29 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 62 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neoplasms, Unknown Primary trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 15 |
| Phase 1/2 | 4 |
| Phase 2 | 33 |
| Phase 2/3 | 1 |
| Phase 3 | 8 |
| Not applicable | 12 |
| Observational | 26 |
| Expanded access | 1 |
How many Neoplasms, Unknown Primary trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 13 |
| Active, not recruiting | 7 |
| Completed | 52 |
| Approved for marketing | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neoplasms, Unknown Primary trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Eastern Cooperative Oncology Group | 2 |
| Travera Inc | 2 |
Which drugs are being tested for Neoplasms, Unknown Primary? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 10 |
| "Capecitabine" | 7 |
| Irinotecan | 6 |
| OXALIPLATIN | 4 |
| Calcium Leucovorin | 4 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 11 |
| Gemcitabine/Gemzar | 10 |
| Cisplatin 1 | 5 |
| Fluorouracile | 5 |
| Radiation Therapy | 4 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neoplasms, Unknown Primary trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dehydration | 24 | 5 |
| Vomiting | 23 | 7 |
| Death | 21 | 2 |
| Febrile Neutropenia | 21 | 1 |
| Neutrophil count decreased | 17 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Neoplasms, Unknown Primary? (105)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 105 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.